As SP Investment Fund LLC manager, Gil Seton oversees investments in biotech companies, including those creating new medical treatment methodologies. One such company that Gil Seton has been responsible for is SP's investment in Coral Genomics (shortened to Coral). Coral utilizes a combination of newly-emerging technologies and preexisting treatment processes to assist as many patients as possible.

Coral Genomics creates genetic sequencing tests and helps hospitals provide precision medicine for patients more quickly and efficiently. The company operates using two principles. The first, equity in precision medicine, assures that all patients, regardless of age, race, or gender, receive quality care. Their clinical trials focus on how different drugs affect different demographics and how to cater drug treatments to each one.

The second principle is called anti-precision medicine. Though seemingly contradictory to Coral’s other operating principles, anti-precision medicine actually expands Coral’s scope. After discovering usable treatments for a specific patient, Coral desires to scale up those findings to assist others. Rather than only focusing on one drug regimen that helps only one patient, they will apply their research to improving preexisting therapies so that all patients may experience the same benefits.